Crawford County Sheriff's Department restoring Project Lifesaver
CRAWFORD COUNTY, Ark. (KNWA/KFTA) — The Crawford County Sheriff's Department and Department of Emergency Management are joining forces to re-establish Project Lifesaver.
Project Lifesaver is a program that aims to help locate individuals with cognitive disorders or autism should they wander or go missing. Relatives of those who have cognitive disorders can sign up for electronic bracelets that can be located using radio waves. The bracelets can be used to help the caretakers find their wearers if they are lost.
'We used to have it several years ago, and that equipment got outdated and over time, it just quit working,' Crawford County Sheriff Daniel Perry said. 'When I took office, we started looking at grants for it.'
The department has received a $6,000 grant from the Alzheimer's Foundation of America to cover the start-up cost, and they plan to renew the grant in future years to pay for any additional equipment they may need as the project expands. The grant will cover about ten bracelets, according to Perry.
Van Buren bans roosters within city limits
Veronica Robins with the Crawford County Department of Emergency Management said that the program costs nothing upfront for participants, and in the future, will only be an annual fee of $5 when the batteries need to be replaced. The only requirement to join the program is for the patient to have a cognitive disorder, including Alzheimer's, dementia, or autism.
'The time frame of saving someone, especially in a severe weather event, like a cold snap that we just had recently and fixing to have. If you have a person get lost in that weather, time is of the essence,' Robins said, 'The faster we can locate them, the more we're able to save that life. And that's our goal in search and rescue, that's our goal in the sheriff's department, is to bring everybody home safely, and as quick as possible.'
The sheriff's department plans to have the program operational by late March 2025. Residents interested in being a part of the program are asked to reach out to either the Crawford County Sheriff's Department by calling (479) 474-2581 or the Crawford County Department of Emergency Management at (479) 471-3260.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Looks like it's up to Hochul to kill the monstrous ‘assisted suicide' bill
New York is on track to become the 12th state to legalize 'assisted suicide' — and with the most radical law yet. The state Senate was rushing to vote late Monday on Sen. Brad Hoylman-Sigal's Medical Aid in Dying Act, with insiders certain the wheels were fully greased for passage. So it'll be up to Gov. Kathy Hochul to wield her veto and prevent a disgraceful mistake. Again, the New York bill breaks new ground — or sinks to a newer low. All 11 other states (Delaware became No. 11 last month) require a waiting period before you get your suicide-meds prescription filled; it's 15 days in Oregon but could be less than 24 hours in New York. The Empire State bill also has no real mechanism for tracking how many deaths it brings: Some commissioner is supposed to review a 'sample' of patient medical records and produce a yearly report to the Legislature on how it's going; that's it. Beyond the details, this is fundamentally about a reinvention of the medical profession: Out goes 'do no harm,' in comes a 'calculation' as to whether a given life is still worth living. With the state, and insurance companies, having a clear financial interest in ending 'marginal' lives and those whose care costs 'too much.' Anyone who wants to die can, in fact, find a way: This is purely about giving 'assisted suicide' the moral force of law, a big first step on the way to euthanasia for those with chronic conditions — even Alzheimer's. Canada is about to expand its law to allow 'doctor-assisted' killing in some cases where the underlying condition is mental disease, such as depression or anxiety. Advocates claim New York's bill covers only people with terminal diagnoses and six months or less to live — but 'terminal' isn't as exact a term as it sounds, and any diagnosis is simply a doctor's best guess. It's entirely appropriate that the chief Democratic resistance to this bill has been among lawmakers of color: Philosophically as well as historically, euthanasia is intimately connected with eugenics. That is: The same geniuses who imagine that humanity can be 'scientifically' improved by eliminating 'inferior characteristics' from the breeding pool also tend to think 'experts' can calculate which lives have values less than zero. Embrace that pseudo-mathematics, and soon enough the smart set will be busy 'helping' the disabled and those suffering chronic illnesses to 'realize' they're better off ending their lives. We have no idea what back-room deals suddenly made this bill a priority at the very end of the legislative session; it certainly wasn't any shift in public opinion. Hochul should do the right thing and kill the bill: At the very least, that'll force its supporters to explain why New York must have fewer safeguards than any state against abuse of a law that turns doctors into executioners.
Yahoo
8 hours ago
- Yahoo
Gut bacteria changes may be warning sign for worsening Parkinson's
Changes in specific bacteria in the mouth and gut of patients with Parkinson's disease could potentially be an early warning sign that symptoms of the condition are getting worse, a study suggests. With the help of artificial intelligence (AI), scientists have linked these shifts to cognitive decline – problems with memory and learning – in people with the disease. They suggest the toxins could one day be used as 'markers' for medics to pinpoint the Parkinson's patients at a higher risk of dementia, as well as being used to help develop targeted treatments for the disease. Parkinson's disease is a progressive condition that affects the brain, with symptoms including involuntary shaking, known as tremors, as well as psychological problems such as depression, loss of balance, trouble sleeping and memory issues. According to the Alzheimer's Society, around a third of people with Parkinson's eventually develop dementia. 'The human gut and oral bacterial communities are increasingly linked to neurodegenerative diseases. Disruptions in the gut-brain axis could trigger inflammation and immune responses that contribute to neuronal damage," Dr Saeed Shoaie, group leader of the quantitative systems biology (QTS) lab at King's College London, said. "A common gum disease bacterium like porphyromonas gingivalis has been discovered as a potential driver of Alzheimer's." For the study, led by experts at King's College London and published in the journal Gut Microbes, scientists analysed 228 spit and stool samples. The samples came from 41 patients with Parkinson's and mild cognitive impairment, which causes problems with thinking and memory, 47 patients with Parkinson's and dementia and 26 healthy patients. The team found that the gut of people with mild cognitive impairment contained more harmful bacteria, many of which are likely to have come from the mouth. This bacteria releases toxins that can damage gut tissue, promote inflammation and potentially affect the brain, according to researchers. For a more in-depth analysis, the team used AI to pinpoint the bacterial species and functions not usually picked up by traditional testing, allowing them to link toxins specifically to cognitive decline. Dr Shoaie added: 'The emerging evidence underscores the potential importance of maintaining oral and gut health in mitigating or slowing neurodegenerative processes. 'As people with Parkinson's become increasingly reliant on carers, routine practices such as oral hygiene and nutritional intake may be neglected. 'Our findings suggest that promoting a healthy microbiome through consistent oral care, a balanced diet and potentially targeted probiotic interventions could support improved disease management in Parkinson's.'
San Francisco Chronicle
2 days ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
